Differential regulation of GluA1 expression by ketamine and memantine

•Memantine potentiates Schaffer collateral-CA1 excitatory synaptic transmission in hippocampal area CA1.•Administration of memantine or ketamine enhances GluA1 S845 phosphorylation, but only ketamine elevates the expression of GluA1.•Memantine-induced potentiation of SC-CA1 synaptic phosphorylation...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Behavioural brain research 2017-01, Vol.316, p.152-159
Hauptverfasser: Zhang, Ke, Yamaki, Vitor Nagai, Wei, Zhisheng, Zheng, Yu, Cai, Xiang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 159
container_issue
container_start_page 152
container_title Behavioural brain research
container_volume 316
creator Zhang, Ke
Yamaki, Vitor Nagai
Wei, Zhisheng
Zheng, Yu
Cai, Xiang
description •Memantine potentiates Schaffer collateral-CA1 excitatory synaptic transmission in hippocampal area CA1.•Administration of memantine or ketamine enhances GluA1 S845 phosphorylation, but only ketamine elevates the expression of GluA1.•Memantine-induced potentiation of SC-CA1 synaptic phosphorylation and GluA1 phosphorylation are not occluded by GAGA receptor blockade.•Ketamine but not memantine enhances the phosphorylation of mTOR, in a time course parallel to the elevation of GluA1 expression.•Neither ketamine or memantine reduces the phosphorylation of eEF2; instead, ketamine enhances eEF2 phosphorylation 30min following administration. Evidence from preclinical and clinical studies shows that ketamine, a noncompetitive NMDA receptor antagonist, exerts rapid and sustained antidepressant responses. However, ketamine’s psychotomimetic side effects and abuse liability limit the clinical use of the compound. Interestingly, memantine, another NMDA receptor channel blocker, processes no defined antidepressant property but is much safer and clinical tolerated. Understanding why ketamine but not memantine exhibits rapid antidepressant responses is important to elucidate the cellular signaling underlying the fast antidepressant actions of ketamine and to design a new safer generation of fast-acting antidepressants. Here we show that ketamine but memantine caused a rapid and sustained antidepressant-like responses in forced swim test (FST). Both drugs enhanced GluA1 S845 phosphorylation and potentiated Schaffer collateral-CA1 synaptic transmission. However, ketamine but not memantine elevated the expression of GluA1. Incubating acutely prepared hippocampal slices with ketamine but not memantine enhanced mTOR phosphorylation in a time course parallel to the time course of GluA1 elevation. Our results suggest that distinct properties in regulation of mTOR phosphorylation and synaptic protein expression may underlie the differential effectiveness of ketamine and memantine in their antidepressant responses.
doi_str_mv 10.1016/j.bbr.2016.09.002
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1837327573</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S016643281630585X</els_id><sourcerecordid>1835370402</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-6c44281ce26e539b2ebb9d4c8c8d1593594b07deb2af1532d80b79403f83df773</originalsourceid><addsrcrecordid>eNqNkMtO5DAQRS0Egh7gA9igLNkk42ccixWChkFCmg2sLT8qyE0ejZ0g-HvcNLBErMoqn3ulOgidEFwRTOq_q8raWNH8rLCqMKY7aEEaSUspuNpFi_xRl5zR5gD9SWmFMeZYkH10QKVQqiZqgZZXoW0hwjAF0xURHufOTGEcirEtbrr5ghTwuo6Q0mZn34onmEwfBijM4IseepODAxyhvdZ0CY4_5yF6uF7eX_4r7_7f3F5e3JWOCzqVteOcNsQBrUEwZSlYqzx3jWs8EYoJxS2WHiw1LRGM-gZbqThmbcN8KyU7RGfb3nUcn2dIk-5DctB1ZoBxTpo0TLJ8nGS_QQWTWQjNKNmiLo4pRWj1OobexDdNsN6I1iudReuNaI2Vxh-Z08_62fbgvxNfZjNwvgUg-3gJEHVyAQYHPkRwk_Zj-KH-HcqBjN0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835370402</pqid></control><display><type>article</type><title>Differential regulation of GluA1 expression by ketamine and memantine</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Zhang, Ke ; Yamaki, Vitor Nagai ; Wei, Zhisheng ; Zheng, Yu ; Cai, Xiang</creator><creatorcontrib>Zhang, Ke ; Yamaki, Vitor Nagai ; Wei, Zhisheng ; Zheng, Yu ; Cai, Xiang</creatorcontrib><description>•Memantine potentiates Schaffer collateral-CA1 excitatory synaptic transmission in hippocampal area CA1.•Administration of memantine or ketamine enhances GluA1 S845 phosphorylation, but only ketamine elevates the expression of GluA1.•Memantine-induced potentiation of SC-CA1 synaptic phosphorylation and GluA1 phosphorylation are not occluded by GAGA receptor blockade.•Ketamine but not memantine enhances the phosphorylation of mTOR, in a time course parallel to the elevation of GluA1 expression.•Neither ketamine or memantine reduces the phosphorylation of eEF2; instead, ketamine enhances eEF2 phosphorylation 30min following administration. Evidence from preclinical and clinical studies shows that ketamine, a noncompetitive NMDA receptor antagonist, exerts rapid and sustained antidepressant responses. However, ketamine’s psychotomimetic side effects and abuse liability limit the clinical use of the compound. Interestingly, memantine, another NMDA receptor channel blocker, processes no defined antidepressant property but is much safer and clinical tolerated. Understanding why ketamine but not memantine exhibits rapid antidepressant responses is important to elucidate the cellular signaling underlying the fast antidepressant actions of ketamine and to design a new safer generation of fast-acting antidepressants. Here we show that ketamine but memantine caused a rapid and sustained antidepressant-like responses in forced swim test (FST). Both drugs enhanced GluA1 S845 phosphorylation and potentiated Schaffer collateral-CA1 synaptic transmission. However, ketamine but not memantine elevated the expression of GluA1. Incubating acutely prepared hippocampal slices with ketamine but not memantine enhanced mTOR phosphorylation in a time course parallel to the time course of GluA1 elevation. Our results suggest that distinct properties in regulation of mTOR phosphorylation and synaptic protein expression may underlie the differential effectiveness of ketamine and memantine in their antidepressant responses.</description><identifier>ISSN: 0166-4328</identifier><identifier>EISSN: 1872-7549</identifier><identifier>DOI: 10.1016/j.bbr.2016.09.002</identifier><identifier>PMID: 27599619</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>AMPA receptor ; Animals ; Benzylamines - pharmacology ; Depression - drug therapy ; Disease Models, Animal ; Excitatory Amino Acid Antagonists - pharmacology ; Excitatory Postsynaptic Potentials - drug effects ; GABA Antagonists - pharmacology ; Gene Expression Regulation - drug effects ; GluA1 Ser845 ; Hippocampus - drug effects ; In Vitro Techniques ; Ketamine ; Ketamine - pharmacology ; Ketamine - therapeutic use ; Major depressive disorder ; Memantine ; Memantine - pharmacology ; Phosphinic Acids - pharmacology ; Phosphorylation - drug effects ; Picrotoxin - pharmacology ; Rats ; Rats, Sprague-Dawley ; Receptors, AMPA - metabolism ; Swimming - psychology ; Synaptic Transmission - drug effects ; Synaptosomes - drug effects ; Synaptosomes - metabolism</subject><ispartof>Behavioural brain research, 2017-01, Vol.316, p.152-159</ispartof><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-6c44281ce26e539b2ebb9d4c8c8d1593594b07deb2af1532d80b79403f83df773</citedby><cites>FETCH-LOGICAL-c452t-6c44281ce26e539b2ebb9d4c8c8d1593594b07deb2af1532d80b79403f83df773</cites><orcidid>0000-0003-0222-553X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bbr.2016.09.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27599619$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Ke</creatorcontrib><creatorcontrib>Yamaki, Vitor Nagai</creatorcontrib><creatorcontrib>Wei, Zhisheng</creatorcontrib><creatorcontrib>Zheng, Yu</creatorcontrib><creatorcontrib>Cai, Xiang</creatorcontrib><title>Differential regulation of GluA1 expression by ketamine and memantine</title><title>Behavioural brain research</title><addtitle>Behav Brain Res</addtitle><description>•Memantine potentiates Schaffer collateral-CA1 excitatory synaptic transmission in hippocampal area CA1.•Administration of memantine or ketamine enhances GluA1 S845 phosphorylation, but only ketamine elevates the expression of GluA1.•Memantine-induced potentiation of SC-CA1 synaptic phosphorylation and GluA1 phosphorylation are not occluded by GAGA receptor blockade.•Ketamine but not memantine enhances the phosphorylation of mTOR, in a time course parallel to the elevation of GluA1 expression.•Neither ketamine or memantine reduces the phosphorylation of eEF2; instead, ketamine enhances eEF2 phosphorylation 30min following administration. Evidence from preclinical and clinical studies shows that ketamine, a noncompetitive NMDA receptor antagonist, exerts rapid and sustained antidepressant responses. However, ketamine’s psychotomimetic side effects and abuse liability limit the clinical use of the compound. Interestingly, memantine, another NMDA receptor channel blocker, processes no defined antidepressant property but is much safer and clinical tolerated. Understanding why ketamine but not memantine exhibits rapid antidepressant responses is important to elucidate the cellular signaling underlying the fast antidepressant actions of ketamine and to design a new safer generation of fast-acting antidepressants. Here we show that ketamine but memantine caused a rapid and sustained antidepressant-like responses in forced swim test (FST). Both drugs enhanced GluA1 S845 phosphorylation and potentiated Schaffer collateral-CA1 synaptic transmission. However, ketamine but not memantine elevated the expression of GluA1. Incubating acutely prepared hippocampal slices with ketamine but not memantine enhanced mTOR phosphorylation in a time course parallel to the time course of GluA1 elevation. Our results suggest that distinct properties in regulation of mTOR phosphorylation and synaptic protein expression may underlie the differential effectiveness of ketamine and memantine in their antidepressant responses.</description><subject>AMPA receptor</subject><subject>Animals</subject><subject>Benzylamines - pharmacology</subject><subject>Depression - drug therapy</subject><subject>Disease Models, Animal</subject><subject>Excitatory Amino Acid Antagonists - pharmacology</subject><subject>Excitatory Postsynaptic Potentials - drug effects</subject><subject>GABA Antagonists - pharmacology</subject><subject>Gene Expression Regulation - drug effects</subject><subject>GluA1 Ser845</subject><subject>Hippocampus - drug effects</subject><subject>In Vitro Techniques</subject><subject>Ketamine</subject><subject>Ketamine - pharmacology</subject><subject>Ketamine - therapeutic use</subject><subject>Major depressive disorder</subject><subject>Memantine</subject><subject>Memantine - pharmacology</subject><subject>Phosphinic Acids - pharmacology</subject><subject>Phosphorylation - drug effects</subject><subject>Picrotoxin - pharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, AMPA - metabolism</subject><subject>Swimming - psychology</subject><subject>Synaptic Transmission - drug effects</subject><subject>Synaptosomes - drug effects</subject><subject>Synaptosomes - metabolism</subject><issn>0166-4328</issn><issn>1872-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtO5DAQRS0Egh7gA9igLNkk42ccixWChkFCmg2sLT8qyE0ejZ0g-HvcNLBErMoqn3ulOgidEFwRTOq_q8raWNH8rLCqMKY7aEEaSUspuNpFi_xRl5zR5gD9SWmFMeZYkH10QKVQqiZqgZZXoW0hwjAF0xURHufOTGEcirEtbrr5ghTwuo6Q0mZn34onmEwfBijM4IseepODAxyhvdZ0CY4_5yF6uF7eX_4r7_7f3F5e3JWOCzqVteOcNsQBrUEwZSlYqzx3jWs8EYoJxS2WHiw1LRGM-gZbqThmbcN8KyU7RGfb3nUcn2dIk-5DctB1ZoBxTpo0TLJ8nGS_QQWTWQjNKNmiLo4pRWj1OobexDdNsN6I1iudReuNaI2Vxh-Z08_62fbgvxNfZjNwvgUg-3gJEHVyAQYHPkRwk_Zj-KH-HcqBjN0</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Zhang, Ke</creator><creator>Yamaki, Vitor Nagai</creator><creator>Wei, Zhisheng</creator><creator>Zheng, Yu</creator><creator>Cai, Xiang</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QG</scope><scope>7TK</scope><orcidid>https://orcid.org/0000-0003-0222-553X</orcidid></search><sort><creationdate>20170101</creationdate><title>Differential regulation of GluA1 expression by ketamine and memantine</title><author>Zhang, Ke ; Yamaki, Vitor Nagai ; Wei, Zhisheng ; Zheng, Yu ; Cai, Xiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-6c44281ce26e539b2ebb9d4c8c8d1593594b07deb2af1532d80b79403f83df773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>AMPA receptor</topic><topic>Animals</topic><topic>Benzylamines - pharmacology</topic><topic>Depression - drug therapy</topic><topic>Disease Models, Animal</topic><topic>Excitatory Amino Acid Antagonists - pharmacology</topic><topic>Excitatory Postsynaptic Potentials - drug effects</topic><topic>GABA Antagonists - pharmacology</topic><topic>Gene Expression Regulation - drug effects</topic><topic>GluA1 Ser845</topic><topic>Hippocampus - drug effects</topic><topic>In Vitro Techniques</topic><topic>Ketamine</topic><topic>Ketamine - pharmacology</topic><topic>Ketamine - therapeutic use</topic><topic>Major depressive disorder</topic><topic>Memantine</topic><topic>Memantine - pharmacology</topic><topic>Phosphinic Acids - pharmacology</topic><topic>Phosphorylation - drug effects</topic><topic>Picrotoxin - pharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, AMPA - metabolism</topic><topic>Swimming - psychology</topic><topic>Synaptic Transmission - drug effects</topic><topic>Synaptosomes - drug effects</topic><topic>Synaptosomes - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Ke</creatorcontrib><creatorcontrib>Yamaki, Vitor Nagai</creatorcontrib><creatorcontrib>Wei, Zhisheng</creatorcontrib><creatorcontrib>Zheng, Yu</creatorcontrib><creatorcontrib>Cai, Xiang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Animal Behavior Abstracts</collection><collection>Neurosciences Abstracts</collection><jtitle>Behavioural brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Ke</au><au>Yamaki, Vitor Nagai</au><au>Wei, Zhisheng</au><au>Zheng, Yu</au><au>Cai, Xiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential regulation of GluA1 expression by ketamine and memantine</atitle><jtitle>Behavioural brain research</jtitle><addtitle>Behav Brain Res</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>316</volume><spage>152</spage><epage>159</epage><pages>152-159</pages><issn>0166-4328</issn><eissn>1872-7549</eissn><abstract>•Memantine potentiates Schaffer collateral-CA1 excitatory synaptic transmission in hippocampal area CA1.•Administration of memantine or ketamine enhances GluA1 S845 phosphorylation, but only ketamine elevates the expression of GluA1.•Memantine-induced potentiation of SC-CA1 synaptic phosphorylation and GluA1 phosphorylation are not occluded by GAGA receptor blockade.•Ketamine but not memantine enhances the phosphorylation of mTOR, in a time course parallel to the elevation of GluA1 expression.•Neither ketamine or memantine reduces the phosphorylation of eEF2; instead, ketamine enhances eEF2 phosphorylation 30min following administration. Evidence from preclinical and clinical studies shows that ketamine, a noncompetitive NMDA receptor antagonist, exerts rapid and sustained antidepressant responses. However, ketamine’s psychotomimetic side effects and abuse liability limit the clinical use of the compound. Interestingly, memantine, another NMDA receptor channel blocker, processes no defined antidepressant property but is much safer and clinical tolerated. Understanding why ketamine but not memantine exhibits rapid antidepressant responses is important to elucidate the cellular signaling underlying the fast antidepressant actions of ketamine and to design a new safer generation of fast-acting antidepressants. Here we show that ketamine but memantine caused a rapid and sustained antidepressant-like responses in forced swim test (FST). Both drugs enhanced GluA1 S845 phosphorylation and potentiated Schaffer collateral-CA1 synaptic transmission. However, ketamine but not memantine elevated the expression of GluA1. Incubating acutely prepared hippocampal slices with ketamine but not memantine enhanced mTOR phosphorylation in a time course parallel to the time course of GluA1 elevation. Our results suggest that distinct properties in regulation of mTOR phosphorylation and synaptic protein expression may underlie the differential effectiveness of ketamine and memantine in their antidepressant responses.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>27599619</pmid><doi>10.1016/j.bbr.2016.09.002</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-0222-553X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0166-4328
ispartof Behavioural brain research, 2017-01, Vol.316, p.152-159
issn 0166-4328
1872-7549
language eng
recordid cdi_proquest_miscellaneous_1837327573
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects AMPA receptor
Animals
Benzylamines - pharmacology
Depression - drug therapy
Disease Models, Animal
Excitatory Amino Acid Antagonists - pharmacology
Excitatory Postsynaptic Potentials - drug effects
GABA Antagonists - pharmacology
Gene Expression Regulation - drug effects
GluA1 Ser845
Hippocampus - drug effects
In Vitro Techniques
Ketamine
Ketamine - pharmacology
Ketamine - therapeutic use
Major depressive disorder
Memantine
Memantine - pharmacology
Phosphinic Acids - pharmacology
Phosphorylation - drug effects
Picrotoxin - pharmacology
Rats
Rats, Sprague-Dawley
Receptors, AMPA - metabolism
Swimming - psychology
Synaptic Transmission - drug effects
Synaptosomes - drug effects
Synaptosomes - metabolism
title Differential regulation of GluA1 expression by ketamine and memantine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T06%3A52%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20regulation%20of%20GluA1%20expression%20by%20ketamine%20and%20memantine&rft.jtitle=Behavioural%20brain%20research&rft.au=Zhang,%20Ke&rft.date=2017-01-01&rft.volume=316&rft.spage=152&rft.epage=159&rft.pages=152-159&rft.issn=0166-4328&rft.eissn=1872-7549&rft_id=info:doi/10.1016/j.bbr.2016.09.002&rft_dat=%3Cproquest_cross%3E1835370402%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835370402&rft_id=info:pmid/27599619&rft_els_id=S016643281630585X&rfr_iscdi=true